Abstract: BaCkground: Mycosis fungoides (MF) is the most common subtype of cutaneous T-cell lymphoma. TNMB system is the staging method used in MF, and it not only guides therapeutic management, but represents the main prognostic factor. In order to improve the prognostic evaluation, the Cutaneous Lymphoma International Prognostic Index (CLIPi) was proposed. oBjeCtive: To evaluate the performance of CLIPi score for prognostic analysis in patients with early stage MF. Methods: This is a retrospective cross-sectional observational study, with exploratory analysis. The outcome variables were disease progression and related death. results: One hundred and two patients were stratified according to CLIPi score, being the majority classified as low risk. Patients with intermediate or high risk presented disease progression more frequently than those with low risk (PR: 1.2 / p = 0.004 / 95%CI: 1.0 -1.6). The same did not occur with the variable related death. In addition, survival rates were not consistent with risk stratification. study liMitations: Small sample and its retrospective analysis. ConClusions: Since CLIPi score was proposed, four other studies that we could consult showed conflicting results, similar to the present study. Further studies are necessary for a recommendation of its use.
INTRODUCTION
Mycosis fungoides (MF) is the most common subtype of cutaneous T-cell lymphoma (CTCL) and has a behavior classified as indolent, with an overall survival in five years of 88%. [1] [2] [3] [4] The current staging is through the TNMB system, proposed and B, extension to peripheral blood. 4, 5 TNMB staging system, albeit not ideal, remains as the main prognostic factor. 
T2
Patches, papules and/or plaques involving more than 10% of the body surface area T2a (Patches)/T2b (Patches and plaques)
T3
One or more tumors (equal to or larger than 1cm)
T4
Confluence of erythema involving at least 80% of the body surface area
Lymph node involvement

N0
No abnormalities in the peripheral lymph nodes
N1
Presence of abnormal lymph node. Dutch grade I on histopathology. N1a (negative clone)/ N1b (positive clone)
N2
Presence of abnormal lymph node. Dutch grade II on histopathology. N2a (negative clone)/ N2b (positive clone)
N3
Presence of abnormal lymph node. Dutch grade III or IV on histopathology. Negative or positive clone. Dutch histopathology grading system for the classification of lymph node involvement is recognized by ISCL/EORTC
Nx
Presence of abnormal lymph node, with no histological evaluation/confirmation
Visceral involvement
M0
No visceral involvement
M1
Presence of visceral involvement, confirmed by histopathology. The organ involved must be specified
Peripheral blood involvement
B0
Absence of peripheral blood involvement (equal to or less than 5% of atypical lymphocytes in the peripheral blood -Sézary cells). B0a (negative clone)/B0b (positive clone)
B1
Presence of more than 5% of atypical lymphocytes, not fulfilling criteria for B2. B1a (negative clone)/B1b (positive clone) The main prognostic factor continues to be the staging according TNMB classification. 5, 14 In this sample, only the presence of plaque lesions was associated to a higher frequency of stage progression. In a study being prepared for publication conducted by the same authors of this study, using the same cases, besides the presence of plaque lesions, disease involvement of more than 10% of the body surface area, abnormal lactic dehydrogenase and beta-2-microglobulin, besides stage IB itself, were identified as poor prognosis factors. Supporting these findings, advanced age at diagnosis, higher than 15% and, finally, detection of TCR clonality in peripheral blood were described as factors of worse prognosis.
1,3,6,9,10,11,14,15
As previously described, to improve prognostic assessment CLIPi score was tested in a group with 60 patients, of which 30 had progressed. The 30 remaining patients, classified as non-progressing, were matched by age with the progression group. A higher percentage of low-risk patients was identified among those who did not progress, however, this difference was not statistically significant.
11
Three other studies that analyzed the CLIPi score were pub- 14 We point out that it is crucial to advance in the prognostic evaluation of MF patients, since a small but significant percentage, even if classified as early stage, courses with disease progression, affecting survival.
CONCLUSION
We conclude that the results of the usage of the CLIPi score in our sample were conflicting, as demonstrated by the relevant literature, therefore requiring new studies for the definition of its applicability. It is important to highlight that the limitations of this study are its retrospective design and its relative small sample. It was mentioned in the studies consulted the initiative of a prospective, multicentric study in Europe, with the goal of analyzing the performance of PROCLIPi; apparently an adjustment to improve accuracy of CLIPi score. We suggest waiting for those publications. q
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